<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04647552</url>
  </required_header>
  <id_info>
    <org_study_id>AOzer</org_study_id>
    <nct_id>NCT04647552</nct_id>
  </id_info>
  <brief_title>Effects of Hydrocortison Treatment on Angiotensin II and Angiotensin II Receptors in Patients With Septic Shock</brief_title>
  <official_title>The Effect of Hydrocortison Treatment on Angiotensin II and Angiotensin Receptors in Patients Suffering From Septic Shock: A Prospective Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inonu University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inonu University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the role of angiotensin II, AT1, and AT2 on catecholomine&#xD;
      responsive and catecholomine resistant septic shock, and the effect of hydrocortisone&#xD;
      traetment on catecholomine resistant septic shock and angiotensin II, AT1, and&#xD;
      AT2.Angiotensin II can be used as a biomarker of vasoplegia observed in refractory septic&#xD;
      shock unresponsive to catecholamine. In these patients; therapeutic effect of hydrocortisone&#xD;
      on hypotension was performed by decreasing AT 2 level, AT2 should be investigated as a&#xD;
      therapeutic target in the treatment of vasoplegia-induced hypotension and SVRI measured by&#xD;
      minimally invasive cardiac output method suggests that it can be used as a useful parameter&#xD;
      in the diagnosis and follow-up of vasoplegia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be enrolled 40 patients diagnosed with septic shock according to Sepsis 3&#xD;
      criteria. The patients with septic shock who needed a noradrenaline infusion rate of up to&#xD;
      0.5µg/kg/min to maintain MAP&gt;65 mmHg will be classified as control group (n=20) and the ones&#xD;
      who required a noradrenaline infusion rate above 0.5µg/kg will be classified as&#xD;
      hydrocortisone group (n=20). Blood samples will be taken for analysis of plasma angiotensin&#xD;
      II, AT1, AT2 levels at the time of diagnosis, one hour after and on the 3rd day of the bundle&#xD;
      and the hydrocortisone treatment. Hemodynamic parameters simultaneously obtain by continuous&#xD;
      minimal invasive cardiac output measurement method will record.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2020</start_date>
  <completion_date type="Actual">February 6, 2021</completion_date>
  <primary_completion_date type="Actual">February 6, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Serum angiotensin II levels</measure>
    <time_frame>0-3 days</time_frame>
    <description>Serum angiotensin II levels</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum angiotensin II reseptor 1 levels</measure>
    <time_frame>0-3 days</time_frame>
    <description>Serum angiotensin II reseptor 1 levels</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum angiotensin II reseptor 2 levels</measure>
    <time_frame>0-3 days</time_frame>
    <description>Serum angiotensin II reseptor 2 levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>28 days</time_frame>
    <description>mortality rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SVRI</measure>
    <time_frame>0-3 days</time_frame>
    <description>systemic vascular resistans index</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">40</enrollment>
  <condition>Shock, Septic</condition>
  <arm_group>
    <arm_group_label>hydrocortisone</arm_group_label>
    <description>The patients with septic shock who required a noradrenaline infusion rate above 0.5µg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <description>The patients with septic shock who needed a noradrenaline infusion rate of up to 0.5µg/kg/min to maintain MAP&gt;65 mmHg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug Steroid</intervention_name>
    <description>hydrocortisone injection</description>
    <arm_group_label>hydrocortisone</arm_group_label>
    <other_name>hydrocortisone</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        This study was enrolled 40 patients diagnosed with septic shock according to Sepsis 3&#xD;
        criteria.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  septic shock patient&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  other causes of end-stage organ failure, immunodeficiency, presence of acute&#xD;
             mesenteric ischemia, vasospastic disease, pregnancy, other shock causes (hypovolemic,&#xD;
             cardiogenic, neurogenic), life expectancy less than 48 hours corticosteroid use in the&#xD;
             last 4 weeks&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ayse Belin B OZER</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inonu University Faculty of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ayse Belin B OZER</name>
      <address>
        <city>Malatya</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ayse Belin OZER</name>
      <address>
        <city>Malatya</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016 Feb 23;315(8):801-10. doi: 10.1001/jama.2016.0287.</citation>
    <PMID>26903338</PMID>
  </reference>
  <reference>
    <citation>Zhang W, Chen X, Huang L, Lu N, Zhou L, Wu G, Chen Y. Severe sepsis: Low expression of the renin-angiotensin system is associated with poor prognosis. Exp Ther Med. 2014 May;7(5):1342-1348. Epub 2014 Feb 20.</citation>
    <PMID>24940436</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 23, 2020</study_first_submitted>
  <study_first_submitted_qc>November 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2020</study_first_posted>
  <last_update_submitted>February 6, 2021</last_update_submitted>
  <last_update_submitted_qc>February 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Inonu University</investigator_affiliation>
    <investigator_full_name>Ayse Belin Ozer</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>Shock, Septic</keyword>
  <keyword>hydrocortisone</keyword>
  <keyword>angiotensin II</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocortisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

